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doi:10.1Objectives:Our objectives were (1) to determine whether elevated Mg2þin controlled hyperkalemic reperfusate
without intervention during ischemia protects the juvenile heart against reperfusion injury; and (2) to identify the
mechanism(s) underlying any protective effect of Mg2þ.
Methods: Langendorff-perfused hearts from juvenile (11- to 14-day-old) guinea pigs were subjected to
mild (30-minute) or severe (45-minute) normothermic global ischemia and 35-minute reperfusion. Hearts
were subjected to controlled hyperkalemic reperfusion without or with various concentrations of Mg2þ (5, 10,
16, 23 mM). The mechanisms underlying the effect of Mg2þ on intracellular Ca2þ ([Ca2þ]i) were also studied
in isolated cardiomyocytes exposed to metabolic inhibition followed by washout using hyperkalemic solutions
(reperfusion).
Results: Sixteen mM Mg2þ conferred maximal cardioprotection as assessed by improved functional recovery
and reduced cardiac injury; this was associated with a significant recovery of cardiac energetics and metabolism
following both mild and severe ischemia. The Mg2þ-induced protection was additive to that of hyperkalemia
following mild ischemia and conferred protection following severe ischemia when hyperkalemia alone had
no significant effect. Elevated Mg2þ in the hyperkalemic reperfusate of cardiomyocytes acutely prevented
[Ca2þ]i loading followingmild metabolic inhibition and augmented the fall in [Ca2þ]i following severe metabolic
inhibition.
Conclusions: This work demonstrates for the first time in juvenile hearts that elevated Mg2þduring controlled
hyperkalemic reperfusion rescues the heart following ischemia, and that this is likely to be facilitated by reduc-
ing [Ca2þ]i which, in turn, would aid metabolic recovery. (J Thorac Cardiovasc Surg 2011;141:1529-37)Existing clinical interventions employed to protect the heart
against reperfusion injury during surgery aim to improve
cardiac function by reducing the metabolic and ionic de-
rangements that occur during ischemia, including the fall
of energy-rich phosphates, the accumulation of lactic
acid, and the rise in the intracellular concentrations of Naþ
([Naþ]i), Mg
2þ ([Mg2þ]i), and Ca
2þ([Ca2þ]i).
1 A common
protective strategy is hyperkalemic cardioplegic arrest,
which depolarizes the plasma membrane and arrests the
heart. Supplementing hyperkalemic cardioplegia with
Mg2þ ([Mg2þ]o) confers additional protection to the adult
heart during coronary artery bypass graft surgery,2 reducing
Ca2þ loading,3 and improving cytosolic free energy.4
It is becoming increasingly evident that controlling the
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The Journal of Thoracic and Carreperfusate without any intervention during ischemia can
also be used to rescue the myocardium.5 Such interventions
include elevated [Mg2þ]o given during reperfusion of iso-
lated rat and human tissue.6,7 However, these studies
using controlled reperfusion have focused on adult hearts.
Because there are differences in the vulnerability to
cardiac insults between adult and juvenile hearts and in
the efficacy of interventions to protect the heart,8,9
strategies that work in the adult heart may not be effective
in the immature heart.
The objectives of this study were (1) to investigate the
cardioprotective action of Mg2þduring controlled hyperka-
lemic reperfusion of juvenile hearts exposed to a mild or se-
vere ischemic insult; and (2) to identify potential
mechanism(s) underlying any protective effect of elevated
[Mg2þ]o using a model of simulated ischemia/reperfusion-
injury isolated cardiomyocytes from juvenile and adult
hearts. Changes in [Ca2þ]i and cardiac energy status are
implicated in determining the cardioprotective efficacy of
controlled reperfusion in the adult heart.5E
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Animals
Juvenile guinea pigs (11 to 14 days old) were killed by cervical disloca-
tion, and the heartswere quickly removed, rinsed in ice coldTyrode solution
(composition inmM: 135NaCl; 5.4 KCl; 2 CaCl2; 1MgCl2; 5 Na-pyruvate,diovascular Surgery c Volume 141, Number 6 1529
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FIGURE 1. Schematic presentation of the experimental protocols fol-
lowed in this study. In control experiments, Langendorff-perfused juvenile
(11-14 days) guinea-pig hearts were exposed to 30 or 45 minutes of normo-
thermic global ischemia followed by reperfusion for 35 minutes with nor-
mal buffer. In the experimental protocols (intervention) hearts were
exposed to 30 or 45 minutes of normothermic global ischemia followed
by 2 or 5 minutes of controlled hyperkalemia reperfusion with or without
Mg2þ (5, 10, 16, or 23 mM).
Abbreviations and Acronyms
HR ¼ heart rate
HPLC ¼ high-performance liquid
chromatography
LVDP ¼ left ventricular developed pressure
LVEDP ¼ left ventricular end diastolic pressure
LDH ¼ lactate dehydrogenase
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S0.33 NaH2PO4, 10 glucose; 10 HEPES-NaOH; at pH 7.3), and allocated
either to experiments involving intact heart preparations or to experiments
involving isolated ventricular myocytes. All animals were cared for in a
stress-free and controlled environment and treated in accordance
with the Home Office Guidance on the Operation of Animals (Scientific
Procedures) Act, 1986 (HMSO, London); the experiments were approved
by the university’s ethical review board. The investigation conforms with
the Guide for the Care and Use of Laboratory animals published by the
USNational Institutes ofHealth (NIHPublicationNo. 85-23, revised 1996).
Isolated Perfused Heart Preparations
Experimental protocols. Excised juvenile hearts were
Langendorff-perfusedwith 100% oxygenated Tyrode solution at a constant
flow of 13 mL minutes1 g1 wet weight; resulting in an average perfusion
pressure of 60 mm Hg. Hearts were perfused to allow stabilization for 30
minutes before induction of global ischemia (30 or 45 minutes) induced
by switching off the pump and immersing the heart in Tyrode solution at
37C. In the control group, reperfusion was restarted with normal Tyrode
for 35 minutes. In the experimental groups, there was an initial 2- or
5-minutes reperfusion with hyperkalemic buffer (20 mM Kþ) and [Mg2þ]
of 5, 10, 16, or 23 mM (see Figure 1).
Measurements of functional recovery. Functional recovery
on reperfusion was assessed by measuring left ventricular developed pres-
sure (LVDP), left ventricular end diastolic pressure (LVEDP), and heart
rate (HR). Ventricular pressure was measured by inserting a latex balloon
into the left ventricle through the mitral valve. The balloon was tied to the
end of a polyethylene tube connected to pressure transducer, filled with wa-
ter, and kept isovolumic throughout. Six hearts with LVDP>50 mm Hg
were used for each intervention, giving a total of 72 animals.
Determinization of reperfusion injury. Lactate dehydroge-
nase (LDH) leakage into coronary effluent during reperfusion was mea-
sured to determine the extent of cell damage. Coronary effluent was
collected for a 30-second period just before ischemia and at intervals for
30 minutes after ischemia. The activity of LDH was determined using
a diagnostic kit from Sigma (Gillingham, UK), and the values are expressed
as IU/mL.
Measurement of myocardial metabolites. Hearts from a sep-
arate group of juvenile guinea pigs were used to collect myocardial tissue
for the measurement of metabolites. Three myocardial biopsies were col-
lected from perfused hearts at the beginning and end of ischemia and at
the end of controlled hyperkalemic reperfusion without or with 16 mM
Mg2þ. This concentration of Mg2þwas selected because it induced maximal
protection (see Results). Biopsies were immediately frozen and stored in
liquid nitrogen for analysis of metabolites.
Frozen tissue samples were crushed to powder in liquid nitrogen, trans-
ferred to ice-cold 4.8% perchloric acid, mixed, and centrifuged at 15003 g
for 10 minutes at 4C. The supernatant was then neutralized using 0.44 M
K2CO3 and was centrifuged again at 15003 g for 10 minutes at 4
C, after
which the supernatant was collected for high-performance liquid chroma-
tography (HPLC) analysis. The pellet was taken for the measurement of
protein concentration using a Sigma Protein Assay Kit. The concentrations1530 The Journal of Thoracic and Cardiovascular Surof adenine nucleotides (ATP, ADP, and AMP) and other byproducts of ATP
catabolism (the nucleosides inosine and adenosine, and the purines hypo-
xanthine and xanthine) were measured using a Beckman HPLC machine
as described previously.10 Myocardial lactate in the extract was measured
using a commercially available kit from Sigma. The concentration of me-
tabolites was expressed as nmol/mg protein.
The energy status of myocardial tissue before ischemia and after reper-
fusion was determined by calculating the adenylate energy charge. This is
an index of the metabolic status and reflects the ability of the cell to make
energy-rich phosphates from precursors and was calculated as follows:
Energy Charge ¼ ð0:5 ADPþATPÞ=ðAMPþADPþATPÞ
The ratios ATP/ADP and ATP/AMP were calculated and used to reflect
the phosphorylation potential of the cardiomyocyte.
Isolated Perfused Ventricular Cardiomyocyte
Preparations
Isolation of ventricular cardiomyocytes and measure-
ment of fluorescence. Single ventricular cardiomyocytes were
isolated as previously described11 and stored in isolation buffer (composi-
tion in mM: 20 Na HEPES, 130 NaCl, 4.5 KCl, 5 MgCl2, 1 NaH2PO4, 21
glucose, 5 pyruvate, and the pH adjusted to 7.25 with NaOH) plus 2 mM
CaCl2 until use.
For measurement of intracellular [Ca2þ] ([Ca2þ]i), 3 mL of cell suspen-
sion were incubated with 10 mM indo-1 acetoxymethyl ester (indo-1/AM)(-
Molecular Probes, Invitrogen, Paisley, UK) [or 10 minutes at 35C; this
promotes cytosolic loading of the indicator with little mitochondrial com-
partmentation.12 Cells were centrifuged for 1 minute at 1500 3 g and re-
suspended in 5 mL of isolation buffer containing 2 mM CaCl2. A small
portion of the indo-1-loaded cells was placed in an experimental chamber
mounted on the stage of an inverted microscope (Nikon Diaphot 300). The
normal Tyrode superfusate contained (mM): 137NaCl, 5 KCL, 1.2MgSO4,
1.2 NaH2PO4, 16 D-glucose, 2 CaCl2, 20 HEPES, adjusted to pH 7.4 with
NaOH at 37C. The myocyte to be studied was illuminated by a red light
and its image visualized using a TV camera and monitor. Indo-1 was ex-
cited at 350  5 nm and emission was detected at 410  5 nm and 490
 5 nm; results were presented as the 410/490 ratio. Fluorescent light
was detected and collected on-line by a Newcastle Photometric Systemsgery c June 2011
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FIGURE 2. Effect of 16 mMMg2þduring hyperkalemic controlled reper-
fusion on functional recovery (LVDP) and cardiac injury (LDH release) in
isolated perfused juvenile hearts exposed to a mild ischemic insult. Mea-
surements were made prior to ischemia and at different time points during
reperfusion for LVDP (A) and LDH (B). Data are presented as mean 
SEM (n ¼ 6/group). LVDP in the control group was significantly
(P<.05) lower during reperfusion at all time points taken after 5 minutes.
*P<.05 vs other groups at same time point. **P<.05 vs control at same
time point.
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up to 1 data point per 30 ms from a single myocyte.
Metabolic Inhibition and Experimental Protocols
Two experimental models of metabolic inhibition and washout (reperfu-
sion), both severe and mild, were used to investigate the effects of 16 mM
[Mg2þ]o on [Ca
2þ]i. In each model juvenile myocytes were superfused with
normal Tyrode solution to obtain steady-state cardiomyocyte activity, indi-
cated by a response to field stimulation with no arrhythmias, before induc-
tion of metabolic inhibition by superfusion with buffer devoid of glucose
containing 5 mM NaCN. In control myocytes reperfusion was induced
by return to normal Tyrode, and experimental groups were reperfused for
2 or 5 minutes with hyperkalemic buffer without or with 16 mM Mg2þ.
Clearly this is not technically reperfusion because myocytes are continu-
ously superfused, but we find it useful when describing the various
protocols and for comparison with the whole heart experiments.
Model 1: Mild metabolic inhibition. This model aimed to in-
duce a Ca2þload only upon reperfusion but not during metabolic inhibition.
Myocytes were superfused for 45minutes with buffer devoid of glucose and
containing 5mMNaCN and stimulated at 0.4 Hz before reperfusion with orThe Journal of Thoracic and Carwithout hyperkalemia (20 mM Kþ)  16 mM [Mg2þ]o for 30 minutes. All
cells recovered Ca2þ transients and contractile response to stimulation.
Model 2: Severe metabolic inhibition. Myocytes were stimu-
lated at 2 Hz and exposed tometabolic inhibition until they underwent rigor
contracture. Cells were allowed to stay in rigor for 10 minutes, which in-
duced a marked rise in [Ca2þ]i during the insult. Previously we have found
that [Ca2þ]i increases only following rigor development in this model and
that recovery correlates with the extent of the [Ca2þ]i increase.
11
Statistical Analysis
Data are expressed as mean SEM. Statistical analysis was performed
using a StatView package. The statistical significance of the data was de-
termined by using Student t test and where appropriate analysis of variance
(ANOVA, factorial or repeated measures) combined with Fisher protected
least significant difference post hoc test. Differences were accepted as sig-
nificant when P<0.05. Total release of LDH was calculated as area under
the curve using the Trapezium rule available in Excel.
RESULTS
Effect of Mg2þDuring Hyperkalemic-Controlled
Reperfusion of Isolated Perfused Hearts
Mild ischemia. Controlled reperfusion for 2 minutes with
hyperkalemia resulted in cardiac arrest during the con-
trolled reperfusion period but subsequently in improved re-
covery and reduced injury (Figure 2). The presence of
16 mM [Mg2þ]o in the hyperkalemia conferred a significant
additional improvement in recovery (Figure 2), but the ad-
dition of other concentrations ofMg2þdid not show a further
improvement (Figure 3, A). Cardiac cell injury, as assessed
by time-dependent LDH release, was also reduced by hy-
perkalemia plus Mg2þand to a greater extent than by hyper-
kalemia alone (Figure 3, B), although the total LDH release
did not reach statistical significance (Figure 3, B). The full
hemodynamic data for control and for hyperkalemia with or
without 16 mM Mg2þ are given in Table 1.
Severe ischemia. In the experiments, hyperkalemia alone
improved recovery to more than 70%, which may explain
the relatively small beneficial effect of Mg2þ. Therefore
hearts were exposed to global normothermic ischemia for
45 minutes which, as expected, resulted in greater func-
tional impairment and cell injury (LDH release) upon reper-
fusion than did 30minutes of ischemia (Figure 4). However,
2 minutes of hyperkalemic-controlled reperfusion with or
without Mg2þ did not show a significant improvement in
hearts exposed to 45 minutes of ischemia (data not shown).
Therefore a series of experiments were carried out to deter-
mine whether there was an optimal duration of controlled
reperfusion with hyperkalemia plusMg2þthat was effective.
A duration of 5 minutes of hyperkalemic-controlled reper-
fusion with 16 mMMg2þwas cardioprotective and reduced
reperfusion injury in hearts exposed to a severe ischemia in-
sult of 45 minutes’ duration (Figure 4). Hyperkalemia alone
or with 5 mM Mg2þdid not protect, even though it arrested
the heart, whereas other Mg2þ concentrations (10 and 23
mM) conferred significant protection (Figure 3, C and D).
The full hemodynamic data for control and hyperkalemia
with or without 16 mM Mg2þ are given in Table 2.diovascular Surgery c Volume 141, Number 6 1531
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FIGURE 3. Effect of different concentrations of extracellular Mg2þ during hyperkalemic controlled reperfusion in isolated perfused juvenile hearts
exposed to a mild (A and B) or severe (C and D) ischemic insult. Functional recovery was calculated as the final measurement of RPP (rate pressure product)
as percentage of basal level (A and C). Cardiac injury (total LDH release) is shown in B and D. Data are presented as mean SEM (n¼ 6/group). *P<.05 vs
control. **P<.05 vs control and 20Kþ.
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Controlled Hyperkalemic Reperfusion With or
Without Mg2þ
Experiments described thus far have shown that the car-
dioprotective efficacy of 16 mM Mg2þ in the hyperkalemic
reperfusate depends on both the duration of the ischemia
and the duration of the controlled reperfusion with Mg2þ;
protection was most evident after a severe ischemic insult.
Hyperkalemia alone was effective only following mild is-
chemia. This is intriguing because hyperkalemia induces
cardiac arrest (and presumably metabolic preservation)TABLE 1. Hemodynamic parameters I*
Control Experimental
Normal buffer 20 Kþ 20 Kþ, 16 Mg2þ
Basal
LVDP (mm Hg) 66  3 68  2 64  2
HR 232  7 229  7 237  9
LVEDP (mm Hg) 2.3  0.8 2.6  0.6 3.2  0.6
End of reperfusion
LVDP (mm Hg)
(% recovery)
34  3y (52%) 49  2 (74%) 57  2 (89%)
HR (% recovery) 232  10 (97%) 227  10 (100%) 224  4 (95%)
LVEDP (mm Hg) 15.7  2.0y,z 8.3  1.0y 6.7  0.7y
HR, heart rate; LVDP, left ventricular developed pressure; LVEDP, left ventricular end
diastolic pressure. *Hemodynamic parameters were measured before and after 30
minutes of ischemia with or without 2 minutes of controlled reperfusion. End-of-
reperfusion measurements were made after 35 minutes of reperfusion. Mean  SE
(n ¼ 6/group). yP<.05 vs corresponding basal level. zP<.05 vs end of reperfusion
for other groups.
1532 The Journal of Thoracic and Cardiovascular Surunder both conditions. Therefore, the effect of controlled
reperfusion onmyocardial metabolites followingmild or se-
vere ischemia was studied (Figure 5 and Tables 3 and 4).
As expected, following 30 minutes of (mild) ischemia,
there was a fall in ATP and a rise in myocardial lactate in
myocardial biopsies collected at the end of the ischemic
periods (Figure 5, A and B). The presence of 16 mM Mg2þ
did not appear to alter levels of these metabolites after 2
minutes of controlled reperfusion (Figure 5, A and C) de-
spite the hearts’ showing better recovery (Figure 2). How-
ever, the ATP/ADP and ATP/AMP ratios were better
maintained in the Mg2þgroup (Table 3).
By contrast, following 45 minutes of ischemia and 5 min-
utes of controlled reperfusion, ATP levels were significantly
higher in the group containing Mg2þ, whereas lactate levels
were significantly lower than with hyperkalemia alone
(Figure 5, C and D). Again, the ATP/ADP, ATP/AMP ratios
and energy charges were also better preserved in the Mg2þ-
treated group (Table 4). Changes in other metabolites are
shown in Tables 3 and 4.The Effect of Mg2þ on Intracellular Ca2þ in
Isolated Perfused Cardiomyocytes During
Hyperkalemic-Controlled Reperfusion Following
Metabolic Inhibition
To determine whether the protective effect of Mg2þ
resulted from reduced Ca2þ loading, isolated ventricular
myocyteswere used to investigatewhether therewas a directgery c June 2011
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FIGURE 4. Effect of 16 mMMg2þduring hyperkalemic controlled reper-
fusion on functional recovery (LVDP) and cardiac injury (LDH release) in
isolated perfused juvenile hearts exposed to a severe (45-minute) ischemic
insult. Measurements were made prior to ischemia (basal) and at different
time points during reperfusion for LVDP (A) and LDH (B). Data are pre-
sented as mean  SEM (n ¼ 6/group). LVDP in the 20 K, 16 Mg group
was significantly (P< .05) lower during reperfusion at all time points.
*P< .05 vs other groups at same time point. **P< .05 vs control at
same time point.
TABLE 2. Hemodynamic parameters II*
Control Experimental
Normal buffer 20 Kþ 20 Kþ, 16 Mg2þ
Basal
LVDP (mm Hg) 61  1 61  1 62  2
HR 227  4 229  6 33  6
LVEDP (mm Hg) 3.9  0.8 5.1  0.5 4.6  0.7
End of reperfusion
LVDP (mm Hg)
(% recovery)
10.6  1.7y
(17%)
15.4  3.6y
(26%)
31.2  2.2y,z
(50%)
HR (% recovery) 219  8 (97%) 229  7 (100%) 228  5 (98%)
LVEDP (mm Hg) 30.1  6.2y 27.6  3.2y 15.4  2.0y,z
HR, heart rate; LVDP, left ventricular developed pressure; LVEDP, left ventricular end
diastolic pressure.*Hemodynamic parameters measured before and after 45 minutes
of ischemia with or without 5 minutes of controlled reperfusion. End of reperfusion
measurements were made after 35 minutes of reperfusion. Mean SE (n¼ 6/group).
Changes in myocardial metabolites in ventricular biopsies collected before(basal),
end of 30 minutes ischemia, and 2 minutes after controlled reperfusion with 20Kþ
or 20Kþ, 16Mg2þ. Mean  SE (n ¼ 6/group). yP<.05 vs corresponding basal level.
zP<.05 vs end of reperfusion for other groups.
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2þ]i] during mild or
severe models of metabolic inhibition followed by washout
of inhibitors (reperfusion; see Methods).
In the mild model, cells stimulated at 0.4 Hz were ex-
posed to metabolic inhibition (5 mM NaCN, no glucose)
for 45 minutes followed by return to normal Tyrode (con-
trol) or subjected to controlled hyperkalemic reperfusion
without or with 16 mM Mg2þ. In control cells [Ca2þ]i
increased only on reperfusion, and this increase was sus-
tained for the reperfusion period (Figure 6, A). Controlled
reperfusion with hyperkalemia alone did not significantly
alter this trend. However, the addition of 16 mM Mg2þ
greatly limited the increase in [Ca2þ]i, on reperfusion, which
returned to the prehypoxic level (Figure 6, A). Throughout
this time there was little change in myocyte morphology
or contractility, with cells continuing to respond in time
with the stimulus.The Journal of Thoracic and CarIn the severe model, myocytes stimulated at 2 Hz were
exposed to metabolic inhibition (5 mM NaCN, no glucose)
until they entered the rigor state. Cells were allowed to re-
main in rigor for 10 minutes, during which time there was
a marked and significant rise in [Ca2þ]i (Figure 6, B). Reper-
fusion with normal buffer and basal stimulation (0.2 Hz) re-
sulted in a further small rise in resting [Ca2þ]i before [Ca
2þ]i
declined gradually, although remaining significantly higher
than basal levels (Figure 6, B). Controlled hyperkalemic re-
perfusion without or with 16 mM Mg2þaccelerated the fall
of [Ca2þ]I; in the Mg
2þ-treated group, the final [Ca2þ]i was
not significantly different from basal levels (Figure 6, B).
At the end of reperfusion, only 17% of cells contracted in
time with the stimulus, and 50% showed Ca2þ transients.
For the hyperkalemia group these values were 33% and
67%, respectively, whereas for the added 16 mM Mg2þ
group the recovery was 67% and 100% for contraction
and Ca2þ transients, respectively.
DISCUSSION
This work demonstrates for the first time that in juvenile
hearts controlled hyperkalemic reperfusion with elevated
[Mg2þ]o rescues the heart from reperfusion injury. The effi-
cacy of Mg2þ depends on its concentration as well as on
the durations of both ischemia and controlled reperfusion.
It is important to note that after severe ischemia, elevated
[Mg2þ]o was effective in preventing reperfusion damage
when hyperkalemia alone was ineffective; this was associ-
ated with improved cardiac metabolism and energy status.
Experiments using an isolated myocyte model of metabolic
inhibition demonstrated that elevated [Mg2þ]o during con-
trolled hyperkalemic reperfusion acutely inhibited Ca2þ
loading. This reduced Ca2þ loading is therefore likely to
be the cause of improved metabolic recovery at the end of
controlled hyperkalemic reperfusion with elevated [Mg2þ]o.diovascular Surgery c Volume 141, Number 6 1533
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FIGURE 5. Effect of 16 mM Mg2þ during hyperkalemic controlled reperfusion on myocardial concentration of ATP (A and B) and lactate(C and D) in
biopsies collected from isolated perfused juvenile hearts at the beginning (basal) and end of a mild (A and C) or severe (B and D) ischemic insult followed
by 2 or 5 minutes of controlled reperfusion (intervention). Data are presented as mean SEM. *P<.05 vs basal level. **P<.05 vs corresponding basal and
intervention levels. yP<.05 vs the -Mg2þ intervention group.
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hearts is not currently known. Studies of adult hearts or com-
paring adult and aged hearts investigated the effect of elevated
[Mg2þ]o; hyperkalemia was introduced during index ische-
mia,3,13-15 although not during reperfusion (as in this study),
and this also correlated with a reduction in Ca2þ loading.
Mg2þ, Hyperkalemia, and Protection of the Juvenile
Heart
During postnatal development, cardiomyocytes undergo
morphologic, metabolic, energetic, and ionic changes,16,17TABLE 3. Changes in metabolites I*
20Kþ
Metabolites and ratios Basal Ischemia Controlled re
ATP 28.9  2.1 10.3  1.8y 9.3  1
ADP 26.0  3.7 11.3  2.5y 10.7  0
AMP 13.4  3.4 14.9  2.9 8.1  0
IMP 4.7  1.3 7.3  2.0 8.2  1
Inosine 3.25  0.66 9.95  2.26y 5.9  0
Adenosine 0.26  0.04 0.26  0.05 0.26  0
Hypoxanthine 0.90  0.22 2.95  0.62y 1.70  0
ATP/ADP 1.19  0.14 0.96  0.12y 0.86  0
ATP/AMP 2.85  0.69 0.82  0.23y 1.28  0
Adenylate energy charge 1.10  0.16 0.77  0.07y 0.97  0
HR, heart rate; LVDP, left ventricular developed pressure; LVEDP, left ventricular end dia
before(basal), at end of 30 minutes of ischemia, and 2 minutes after controlled reperfusion w
level zP<.05 vs corresponding basal and ischemic levels.
1534 The Journal of Thoracic and Cardiovascular Surso it is not surprising that there are controversies
regarding age-related differences in vulnerability to cardiac
insults and in the efficacy of various cardioprotective strat-
egies.18,19 With the advent of recent strategies to protect the
adult heart by controlling the conditions of reperfusion
without intervention during ischemia,20,21 it has become
essential to determine whether the juvenile heart can also
be protected using this approach. Our choice to use
hyperkalemic solutions to investigate the efficacy of
elevated [Mg2þ]o is important because they form the basis
of cardioplegic solutions used during the ischemic period20Kþ, 16Mg2þ
perfusion Basal Ischemia Controlled reperfusion
.2y 28.7  2.4 10.0  1.2y 11.9  1.9y
.9y 24.5  2.7 12.6  1.72y 10.3  1.1y
.9y 10.5  1.7 12.8  1.8 8.0  1.6y
.4 4.6  1.1 8.3  0.9y 8.4  1.6y
.73z 2.26  0.39 9.76  1.52y 6.78  1.0y
.02 0.27  0.05 0.26  0.04 0.25  0.04
.20y 0.93  0.11 2.89  0.40y 1.83  0.30y
.08y 1.2  0.09 0.83  0.08y 1.19  0.19
.29y 3.04  0.44 0.85  0.13y 1.76  0.33y
.16 0.95  0.08 0.72  0.02y 0.84  0.09
stolic pressure.*Changes in myocardial metabolites in ventricular biopsies collected
ith 20Kþor 20Kþ, 16Mg2þ. Mean SE (n¼ 6/group). yP<.05 vs corresponding basal
gery c June 2011
TABLE 4. Changes in metabolites II*
20Kþ 20Kþ, 16Mg2þ
Metabolites and ratios Basal Ischemia Controlled reperfusion Basal Ischemia Controlled reperfusion
ATP 28.8  2.5 5.5  1.0y 4.1  0.3y 30.9  2.8 5.1  0.7y 10.1  2.1z
ADP 24.4  2.1 8.3  1.0y 7.9  0.5y 27.1  1.6 7.7  1.0y 11.3  1.0y
AMP 12.1  0.4 11.9  1.0 9.0  0.8y 11.1  0.5 11.7  0.9 7.9  2.0
IMP 4.4  0.4 11.9  0.6y 11.2  0.8y 4.7  0.4 11.4  1.6y 9.1  1.7y
Inosine 2.2  0.3 11.3  0.9y 8.1  0.7y 2.2  0.5 11.4  1.0y 6.9  1.6y
Adenosine 0.29  0.03 0.41  0.08 0.41  0.07 0.29  0.05 0.42  0.05 0.47  0.11
Hypoxanthine 0.88  0.09 3.66  0.25y 2.43  0.29z 0.93  0.10 3.67  0.31y 1.90  0.36z
ATP/ADP 1.20  0.12 0.64  0.06y 0.53  0.03z 1.14  0.07 0.67  0.06y 0.85  0.10y
ATP/AMP 2.38  0.19 0.45  0.06y 0.48  0.07y 2.83  0.32 0.46  0.08y 1.54  0.33z
Adenylate energy charge 1.35  0.13 0.99  0.11y 1.14  0.17y 1.46  0.20 0.96  0.08y 1.38  0.23x
HR, heart rate; LVDP, left ventricular developed pressure; LVEDP, left ventricular end diastolic pressure. *Changes in myocardial metabolites in ventricular biopsies collected
before (basal), end of 45 minutes of ischemia, and 5 minutes after controlled reperfusion with 20Kþor 20Kþ, 16Mg2þ. Mean SE (n¼ 6/group). yP<.05 vs corresponding basal
level. zP<.05 vs corresponding basal and ischemia levels. xP<.05 vs corresponding ischemia levels.
Imura et al Evolving Technology/Basic Science
E
T
/B
Sto arrest the adult and juvenile myocardium during
surgery.2,22
In this study, following mild ischemia, the protective ef-
fect of elevated [Mg2þ]o over that of hyperkalemia alone
was evident only at 16 mM Mg2þ; other concentrations
showed no difference. By contrast, following a severe ische-
mic insult, elevated [Mg2þ]o at 10, 16, and 23 mM showed
significant protection at a time when hyperkalemia alone
was ineffective. The cardioplegic role of hyperkalemia is
to arrest the heart in diastole, thus preserving energy-rich
phosphates. But it has been suggested that the rationale
for including Mg2þ in cardioplegic solutions is not its cardi-
oplegic properties,4 and that the added benefit of elevated
[Mg2þ]o is likely to be to the result of any or all of the fol-
lowing: (1) an added metabolic effect; (2) reducing Ca2þ
overload; (3) replenishing [Mg2þ]i stores.
Is Protection of the Juvenile Heart by Elevated
[Mg2þ]o Related to Improved Energy Status,
Improved Ca2þHandling, or Both?
Despite its cardioprotective effects following mild ische-
mia, hyperkalemia alone or with elevated [Mg2þ]o did not
significantly alter ATP levels (Figure 3, A). However, post-
ischemic ATP levels have been shown to correlate poorly
with functional recovery23—ATP levels may not be restored
rapidly if there is depletion of the adenine nucleotide
pool1—and better correlation is seen when comparing the
recovery with an adenylate energy charge or ATP/ADP ratio
(Table 3). Mg2þ also reduced myocyte damage, as indexed
by a reduction in the release of LDH during reperfusion
(Figure 2, B).
As expected, the metabolic derangements were more
marked in hearts following a severe ischemic insult
(Figure 5 and Table 4). At the end of controlled reperfusion,
hyperkalemia alone added little change to the metabolite
levels or the cardiac energetics compared to end ischemic
levels (Table 4). By contrast, the addition of Mg2þ to hyper-The Journal of Thoracic and Carkalemia significantly improved metabolic recovery, includ-
ing ATP, lactate, ATP/AMP, and adenylate energy charge
(Figure 5 and Table 4). These data clearly indicate that
one factor responsible for the cardioprotective effect of el-
evated [Mg2þ]o in controlled hyperkalemia is an improve-
ment in metabolism and energetic state. It is worth
emphasizing that the heart is arrested in both conditions
(hyperkalemia alone or hyperkalemia with elevated Mg2þ)
and therefore the metabolic recovery is likely to be caused
by improvement in basal metabolic activity not associated
with contraction.
Our data on isolated perfused cardiomyocytes (Figure 6)
support the view that the cardioprotection with Mg2þ is to
the result of reduced Ca2þ loading; elevated Mg2þprevented
the increase in [Ca2þ]i during reperfusion during mild met-
abolic inhibition (Figure 6, A) and accelerated recovery of
[Ca2þ]i to basal levels on reperfusion during severe meta-
bolic inhibition (Figure 6, B). The efficacy of protection
by elevated [Mg2þ]o during controlled reperfusion with hy-
perkalemia seen in juvenile hearts may be related to the in-
hibition of L-type Ca2þchannels; work on adult guinea-pig
myocytes has shown that Mg2þ inhibits the channel when
present at concentrations of more than 10 mM,24 and this
would indirectly reduce metabolic demands triggered by
a rise in intracellular Ca2þ. The effects of elevated [Mg2þ]o
may not be caused solely by the blocking of the Ca2þchan-
nels; earlier work showed that elevated [Mg2þ]o provided
superior protection than did Ca2þ channel blockers25;
Mg2þmay also replenish intracellular energy stores because
it has been shown that the fall in ATP during ischemia is fol-
lowed very closely by a rise in [Mg2þ]i.
1 Most of the [Mg2þ]i
in the cardiomyocytes is found as Mg-ATP, so the loss of
Mg2þ during ischemia may restrict the repletion of ATP
upon reperfusion.4 This is critical because [Mg2þ]i does
not respond rapidly to elevations in [Mg2þ]o.
25 Therefore
the slow replenishment of [Mg2þ]i may hinder recovery. In-
creasing the inward gradient of Mg2þ would increase itsdiovascular Surgery c Volume 141, Number 6 1535
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FIGURE 6. Effect of 16 mMMg2þduring hyperkalemic controlled reper-
fusion on intracellular Ca2þ concentration ([Ca2þ]i) measured in isolated
superfused cardiac myocytes exposed to mild or severe metabolic inhibi-
tion (see Methods). A, During severe metabolic inhibition myocytes enter
rigor and [Ca2þ]i increases markedly. On restoring normal perfusion condi-
tions, [Ca2þ]i declines back gradually but not to basal levels. Initial con-
trolled hyperkalemic reperfusion with or without 16 mM Mg2þ for 5
minutes accelerated the recovery in [Ca2þ]i. B, During mild metabolic
inhibition, cell morphology and [Ca2þ]i did not alter. However, restoring
normal perfusion conditions induced a significant increase in [Ca2þ]i.
Controlled hyperkalemic reperfusion with Mg2þfor 2 minutes significantly
prevented the rise in [Caþ2]i. However, [Ca
2þ]i remained significantly
higher than basal levels at most time points. Data are presented as mean
 SE (n ¼ 6/group). *P<.05 vs basal level.
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Sinflux and presumably aid in recovery. Exactly how Mg2þ
accelerates the decline in Ca2þ upon the reperfusion seen
in the myocyte model requires further investigation, but
this study nevertheless has important implications for
design of reperfusion-based protective strategies for the
juvenile heart.Study Limitations
Our study utilized both single cells and perfused hearts:
Isolated cardiomyocytes enabled us to monitor cellular
changes in Ca2þwithout interference from the cardiovascu-1536 The Journal of Thoracic and Cardiovascular Surlature. An isolated Langendorff-perfused heart is a starting
model that is widely used to investigate the effects of car-
diac insults and various interventions, including cardiople-
gic solutions. However, this heart model has limitations
because it is not a working heart and is perfused with crys-
talloid buffer rather than blood. Therefore, the cardioprotec-
tive efficacy of Mg2þ in hyperkalemic solution needs to be
further investigated in an in vivo model (eg, piglet) with
or without cardiopulmonary bypass.
We acknowledge the support of the National Institute for Health
Research Bristol Biomedical Research Unit.References
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